[go: up one dir, main page]

Di Minno et al., 1985 - Google Patents

Platelet dysfunction in uremia. Multifaceted defect partially corrected by dialysis

Di Minno et al., 1985

Document ID
9746000569565789914
Author
Di Minno G
Martinez J
McKean M
De La Rosa J
Burke J
Murphy S
Publication year
Publication venue
The American journal of medicine

External Links

Snippet

In an attempt to elucidate the nature of the bleeding tendency in uremia, some in vitro functions of platelets from eight patients undergoing long-term hemodialysis were studied. None of the patients had diabetes. All had bleeding times longer than eight minutes …
Continue reading at www.sciencedirect.com (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Similar Documents

Publication Publication Date Title
Di Minno et al. Platelet dysfunction in uremia. Multifaceted defect partially corrected by dialysis
Pareti et al. Biochemical and metabolic aspects of platelet dysfunction in chronic myeloproliferative disorders
Vanholder et al. Phagocytosis in uremic and hemodialysis patients: a prospective and cross sectional study
Fernandez et al. Low haematocrit and prolonged bleeding time in uraemic patients: effect of red cell transfusions
Heiden et al. Impairment by heparin of primary haemostasis and platelet [14C] 5‐Hydroxytryptamine release
Liu et al. Treatment of uraemic bleeding with conjugated oestrogen
Zwaginga et al. High von Willebrand factor concentration compensates a relative adhesion defect in uremic blood
Kimura et al. Effects of various ginseng saponins on 5-hydroxytryptamine release and aggregation in human platelets
Bressler et al. Concurrent studies of oxygen consumption and aggregation in stimulated human platelets
Levin et al. The interaction of sodium nitroprusside with human endothelial cells and platelets: nitroprusside and prostacyclin synergistically inhibit platelet function.
Brodsky et al. Simultaneous Fibrinogen and Platelet’Survival with [75Se] Selenomethionine in Man
Staudinger et al. Influence of prothrombin complex concentrates on plasma coagulation in critically ill patients
Snapper et al. Effects of platelet depletion on the unanesthetized sheep's pulmonary response to endotoxemia.
Michelson et al. Platelet and platelet-derived microparticle surface factor V/Va binding in whole blood: differences between neonates and adults
Miller et al. Effect of fish oil concentrates on hemorheological and hemostatic aspects of diabetes mellitus: a preliminary study
Teien et al. Heparin elimination in uraemic patients on haemo‐dialysis
Barbui et al. Aspirin and risk of bleeding in patients with thrombocythemia
Hladovec et al. Protection by flunarizine against endothelial cell injury in vivo
Tyigate et al. Metabolism and Distribution of Fibrinogen 11. FIBRINOGEN TURNOVER IN POLYCYTHAEMIA, THROMBOCYTOSIS, HAEMOPHILIA A, CONGENITAL AFIBRINOGENAEMIA AND DURING STREPTOKINASE THERAPY
Dejana et al. Bleeding time in laboratory animals. III-Do tail bleeding times in rats only measure a platelet defect?(the aspirin puzzle)
Koike et al. Platelet secretion defect in patients with the attention deficit disorder and easy bruising
Sweeney et al. Whole blood aggregation in von Willebrand disease
Minkes et al. Arachidonic acid-induced platelet aggregation independent of ADP-release in a patient with a bleeding disorder due to platelet storage pool disease
Benigni et al. Inhibition of human platelet aggregation by parathyroid hormone: is cyclic AMP implicated?
Castaman et al. Multimeric pattern of plasma and platelet von Willebrand factor is normal in uremic patients